NFL rookie Nic Scourton is suffering from a collapsed lung. The second-round pick initially began showing symptoms during a ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

In 2021, ATYR completed a phase 1b/2a trial in pulmonary sarcoidosis, and have since started a phase 3 trial. Currently the ...

For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they ...

The A5 nanobody is around 10 times smaller than conventional antibodies, helping it to penetrate deep into tissues. Crucially, it can bind selectively to cancer cells, leading to a reduction of more ...

In a significant research advancement that may help inform treatment strategies for millions of patients worldwide, a ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

A federal rule to limit coal miners’ exposure to dangerous silica dust — which was set to go into effect next week after ...